Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
27.66
+5.33 (23.87%)
At close: Oct 9, 2026, 4:00 PM EDT
27.90
+0.24 (0.88%)
After-hours: Oct 9, 2026, 7:38 PM EDT
Cue Biopharma Revenue
Cue Biopharma had revenue of $7.88M in the quarter ending June 30, 2026, with 166.66% growth. This brings the company's revenue in the last twelve months to $37.65M, up 354.37% year-over-year. In the year 2025, Cue Biopharma had annual revenue of $27.47M with 195.75% growth. That makes Cue Biopharma the 29,882nd largest company in the world by revenue and 3,974th in the United States.
Revenue (ttm)
$37.65M
Revenue Growth
+354.37%
P/S Ratio
5.34
Revenue / Employee
$1,298,448
Employees
29
Market Cap
200.93M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.47M | 18.18M | 195.75% |
| Dec 31, 2024 | 9.29M | 3.80M | 69.16% |
| Dec 31, 2023 | 5.49M | 4.25M | 340.96% |
| Dec 31, 2022 | 1.25M | -13.70M | -91.67% |
| Dec 31, 2021 | 14.94M | 11.79M | 373.68% |
| Dec 31, 2020 | 3.15M | -304.01K | -8.79% |
| Dec 31, 2019 | 3.46M | 2.32M | 202.67% |
| Dec 31, 2018 | 1.14M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 74.00M |
| Invivyd | 58.37M |
| Precision BioSciences | 45.06M |
| Alpha Cognition | 15.26M |
| Adagene | 9.29M |
| Whitehawk Therapeutics | 7.15M |
| Entrada Therapeutics | 4.69M |
| Cartesian Therapeutics | 1.48M |
CUE News
- 18 days ago - B. Riley would be ‘aggressive buyers’ of Cue Biopharma after selloff - TheFly
- 18 days ago - Cue Biopharma Transcript: Study result - Transcripts
- 18 days ago - Cue Biopharma Press release: Study result - Filings
- 18 days ago - Cue Biopharma Slides: Study result - Filings
- 19 days ago - Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint - TheFly
- 20 days ago - Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria - GlobeNewsWire
- 22 days ago - Cue Biopharma initiated with a Buy at B. Riley - TheFly
- 7 weeks ago - Cue Biopharma registers to sell 1.5M shares of common stock for holders - TheFly